<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745170</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308E301</org_study_id>
    <nct_id>NCT03745170</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer</brief_title>
  <official_title>Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate overall survival of Sintilimab+ oxaliplatin +
      capecitabine and placebo+ oxaliplatin + capecitabine, as first-line treatment for advanced
      gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Overall survival (OS)of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus placebo+oxaliplatin + fluoropyrimidine in all randomized participants;Overall survival(OS) of Sintilimab + oxaliplatin + capecitabine versus placebo+ oxaliplatin + capecitabine in participants with programmed cell death ligand 1 (PD-L1) expressing tumors (CPS&gt;=10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survivla (PFS)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Progression Free Survivla (PFS) of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus placebo+oxaliplatin + fluoropyrimidine in all randomized participants and PD-L1 expression participants(CPS&gt;=10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Duration of Response (DoR) of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus placebo+oxaliplatin + fluoropyrimidine in all randomized participants and PD-L1 expression participants(CPS&gt;=10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Objective Response Rate (ORR) of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus placebo+oxaliplatin + fluoropyrimidine in all randomized participants and PD-L1 expression participants(CPS&gt;=10) per RESIST v1,1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Disease Control Rate (DCR) of Sintilimab + oxaliplatin + capecitabine versus placebo+ oxaliplatin + capecitabine in in all randomized participants . and PD-L1 expression participants(CPS&gt;=10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Safety of Sintilimab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in all randomized participants and PD-L1 expression participants(CPS&gt;=10)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Sintilimab+ Oxaliplatin +capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo +Oxaliplatin + Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Weight&lt;60Kg: 3mg/kg Q3W Weignt&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion</description>
    <arm_group_label>Sintilimab+ Oxaliplatin +capecitabine</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m^2 Q3W on Day 1 by IV infusion</description>
    <arm_group_label>Sintilimab+ Oxaliplatin +capecitabine</arm_group_label>
    <arm_group_label>placebo +Oxaliplatin + Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14</description>
    <arm_group_label>Sintilimab+ Oxaliplatin +capecitabine</arm_group_label>
    <arm_group_label>placebo +Oxaliplatin + Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Weight&lt;60Kg: 3mg/kg Q3W Weignt&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion</description>
    <arm_group_label>placebo +Oxaliplatin + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or
             metastatic gastric or GEJ adenocarcinoma.

          -  Male or Female at least 18 years and younger than 75 yeas of age

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Did not receive neoadjuvant or adjuvant treatment (chemotherapy, radiotherapy, or
             both) for their disease within the last 6 months

          -  Must agree to provide tumor tissue sample, either from a previous surgery or biopsy ,
             within 6 months or fresh, prior to the start of treatment in this study and Has a
             PD-L1 status determined by immunohistochemistry (IHC) at a central laboratory

          -  Has measurable or non-measurable (but assessable) disease as defined by RECIST 1.1 as
             determined by investigator assessment.

          -  Has adequate organ function.

          -  Expected survival&gt;=12 weeks.

          -  Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy
             test at the timing of enrollment

          -  Participants of childbearing potential must be willing to use an adequate method of
             contraception for the course of the study through 6 months after the last dose of
             study medication

        Exclusion Criteria:

          -  Suspicious active bleeding or obstruction phenomenon and Has difficulty in swallow
             tablets and food

          -  HER2-positive status

          -  Has had previous therapy for unresectable locally advanced, recurrent or metastatic
             gastric/GEJ cancer

          -  Liver metastasis lesion&gt;=50% of liver volume

          -  Has received prior therapy with a dose of cisplatin&gt;=300 mg/m-^2

          -  Has grade â‰¥ 2 peripheral sensory neuropathy

          -  Known DPD enzyme deficiency status (&gt;=grade 3 mucosal toxicity in previous
             fluorouracil treatment)

          -  Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, anti-PD
             L2 , anti-CD137,anti-CTLA-4 agent or with an agent directed to another stimulatory or
             co-inhibitory T-cell receptor

          -  Is currently participating in and receiving study therapy ,except those in the
             survival follow up period of an investigational agent study or non-interventional
             study .

          -  Received systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalent)
             or other immunosuppressive medications within 4 weeks of first dose. Inhaled or
             topical steroids ,adrenal replacement steroid doses and steroid of prevention allergic
             reaction of i.v. contrast agent are permitted in the absence of active autoimmune
             disease.

          -  Received a live vaccine within 4 weeks of the first dose of study medication or plan
             to receive live vaccine during study period.

          -  Has had major surgery (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to
             first dose of study medication, or anticipation of the need for major surgery during
             the course of study treatment

          -  Known symptomatic central nervous system (CNS) metastasis and/or carcinomatous
             meningitis. Subjects received prior treatment and have stable disease more than 4
             weeks from first dose of study medication.

          -  Clinical significant ascites, including which can be detected in percussion, had been
             ever drained or still need to be controlled currently.

          -  Bilateral moderate pleural effusion, or a large amount of pleural effusion on one
             side, or has caused respiratory dysfunction requiring drainage.

          -  Bone metastasis with risk of paraplegia.

          -  Active, known or suspected autoimmune disease or has a history of the disease within
             the last 2 years (subjects with vitiligo, psoriasis, alopecia or Grave's disease,
             residual hypothyroidism due to autoimmune thyroiditis only requiring hormone
             replacement, or type I diabetes mellitus only requiring insulin replacement, but not
             required systemic treatment in the last 2 years, are permitted to enroll) .

          -  Known primary immunodeficiency.

          -  Known active tuberculosis.

          -  Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation.

          -  Known&gt;=grade 3 allergy or hypersensitivity to oxaliplatin,capecitabine or any
             monoclonal antibodies.

          -  Human Immunodeficiency Virus (HIV) infection (HIV antibody positive).

          -  Active or poorly controlled severe infection.

          -  Symptomatic congestive heart failure (New York Heart Association grade II-IV) or
             symptomatic, poorly controlled arrhythmia.

          -  Poorly controlled arterial hypertension (SBP â‰¥ 160mmHg or DBP â‰¥ 100mmHg) with standard
             treatment .

          -  Prior arterial thromboembolism event, including myocardial infarction, unstable
             angina, stroke and transient ischemic attack, within 6 months of enrollment.

          -  Malnutrition requiring intravenous nutrition, subjects with malnutrition correctionâ‰¥4
             weeks are permitted to enroll.

          -  Prior deep vein thrombosis, pulmonary embolism or any other severe thromboembolism
             events (implanted port or catheter caused thrombosis, or superficial vein thrombosis
             are not considered as severe thromboembolism) within 3 months before enrollment.

          -  History of uncontrolled metabolic disorder, non-malignant organ or systemic disease or
             secondary carcinomatous reaction, with high medical risk and/or uncertainty of life
             expectancy evaluation.

          -  With hepatic encephalopathy, hepatorenal syndrome or hepatic cirrhosis of Child-Pugh
             grade B or higher.

          -  History of intestinal obstruction or the following diseases: inflammatory bowel
             disease or extensive bowel resection (partial colonic resection or extensive small
             bowel resection, concomitant with chronic diarrhea), Crohn's disease, ulcerative
             colitis.

          -  Known acute or chronic active hepatitis B infection (positive HBsAg and HBV DNA â‰¥ 200
             IU/mL or â‰¥ 10^3 copies/mL positive) infection or acute or chronic active hepatitis C
             (HCV antibody positive and HCV RNA positive) infection.

          -  History of gastrointestinal perforation and /or fistula within 6 months before
             enrollment.

          -  Subjects with interstitial lung disease requiring steroids therapy.

          -  Other primary malignancy, with the exception of:

               1. Malignancy which achieved complete response for at least 2 years before
                  enrollment and do not need other treatment during study period;Curative
                  malignancy, without active disease in the last 5 years and with very low
                  recurrence risk;

               2. Non-melanoma skin cancer or malignant freckle-like nevus with adequate treatment
                  and no evidence of recurrence ;

               3. Adequately treated in-situ carcinoma.

          -  Women who are pregnant or nursing.

          -  Other acute or chronic diseases, mental illness, or abnormal laboratory test results
             that may lead to the following outcomes: increase the risk of participating in study
             or study drug administration, or interfere with the interpretation of the study
             results and considered by investigator as &quot;NOT&quot; eligible to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mengmeng Ci</last_name>
    <phone>8613911509423</phone>
    <email>mengmeng.ci@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>People's Liberation Army No. 307 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Xu</last_name>
      <phone>+86010-66947176</phone>
      <email>Jianmingxu2014@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

